Breakthrough in mRNA vaccines for melanoma

Source: News GP, December 2022

A new ‘personalised’ mRNA cancer vaccine in combination with pembrolizumab (sold as Keytruda) significantly improves recurrence-free survival from melanoma, Moderna and Merck have announced.

The combination of the mRNA vaccine and pembrolizumab, an immunotherapy drug, was given as adjuvant treatment to patients with stage III/IV melanoma following complete resection as part of the KEYNOTE/mRNA trial, which showed it reduced the risk of recurrence or death by 44% compared to pembrolizumab alone.

Associate Professor Jeremy Hudson, Clinical Director of the North Queensland Skin Centre, told newsGP he is delighted by the news.
READ THE ORIGINAL FULL ARTICLE